2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Classical hematology
1
Conditions
Treatment of Venous Thromboembolism in Cancer Patients
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
1033
Carboplatin
971
Paclitaxel
942
Gemcitabine
799
Cisplatin
757
Docetaxel
698
Bevacizumab
637
Nivolumab
520
Pemetrexed
507
Capecitabine
475
Cyclophosphamide
473
Fluorouracil
425
Dexamethasone
410
Rituximab
391
Oxaliplatin
352
Injections
347
Trastuzumab
313
atezolizumab
312
Cetuximab
291
Leucovorin
290
Irinotecan
271
130-nm albumin-bound paclitaxel
257
Prednisone
251
Ipilimumab
244
Doxorubicin
241
Lenalidomide
231
Fulvestrant
226
fludarabine
219
durvalumab
211
Erlotinib Hydrochloride
196
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
N(4)-oleylcytosine arabinoside
×
Clear all
NCT05498428
2026-05-08
PALOMA-2
Janssen Research & Development, LLC
Phase 2
Recruiting
520 enrolled
NCT04979780
2024-10-31
OSCAR-US
Bayer
Completed
3,708 enrolled